Health
CRYSVITA® Now Publicly Reimbursed for the Treatment of Adults with XLH in Four Provinces and Federal Non-Insured Health Benefits Program
Public drug coverage now provides eligible adults access to CRYSVITA, the only approved treatment for X-linked hypophosphatemia (XLH), a lifelong progressive disease TORONTO, May 06, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin Canada, a wholly owned subsidiary of Kyowa Kirin Inc., is pleased to announce that CRYSVITA® (burosumab injection) is now publicly funded for eligible adults living with X-linked hypophosphatemia in Ontario, British Columbia, Saskatchewan, and Alberta, as well as through the fede
About this update from Kyowa Kirin Co., Ltd.
[{"type":"image","alt":"Kyowa Kirin","displaySize":"","headline":null,"caption":"Kyowa Kirin","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":58,"url":"https://media.zenfs.com/en/globenewswire.com/b9c3225d04b222adf60766e494f98867"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fIKdZA6jEi2DlyHW8g1mHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgx/https://media.zenfs.com/en/globenewswire.com/b9c3225d04b222adf60766e494f98867","width":300,"height":58}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Public drug coverage now provides eligible adults access to CRYSVITA, the only approved treatment for X-linked hypophosphatemia (XLH), a lifelong progressive disease","length":165,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":165,"olType":false},{"type":"text","content":"TORONTO, May 06, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin Canada, a wholly owned subsidiary of Kyowa Kirin Inc., is pleased to announce that CRYSVITA® (burosumab injection) is now publicly funded for eligible adults living with X-linked hypophosphatemia in Ontario, British Columbia, Saskatchewan, and Alberta, as well as through the federal Non-Insurance Health Benefits program—significantly expanding access beyond those with private insurance.","length":443,"tagName":"p"},{"type":"text","content":"“The XLH community has long called for broader access to innovative therapies for Canadian adults living with XLH, and we are excited that this day has finally come,” said Shari-lin Van Vugt, Chair of the Canadian XLH Network. “The expansion of public drug coverage fills a meaningful gap in care, ensuring more people living with XLH can obtain timely, appropriate treatment.”","length":377,"tagName":"p"},{"type":"text","content":"XLH is a rare, lifelong, genetic disease that can impact the bones and muscles of both children and adults due to excessive loss of phosphorus. Although CRYSVITA is indicated for the treatment of XLH in adult and pediatric patients 6 months of age and older, publicly funded coverage had been limited to pediatric patients who are at least one year of age and in whom epiphyseal closure has not yet occurred.","length":408,"tagName":"p"},{"type":"text","content":"“Because XLH is a progressive disease that may continue to worsen through adulthood, Kyowa Kirin has continued to advocate for timely, ongoing access to e...